CymaBay Therapeutics
Gilead Sciences is committed to creating a healthier world for all people through innovation and the development of transformative therapies. With a focus on virology, oncology, and inflammation, Gilead invests in world-class science to combat some of the world's most devastating diseases. The company fosters an inclusive workplace with over 18,000 employees worldwide, dedicated to advancing scientific innovation, ensuring medicines reach those in need, and making a positive impact in communities. Gilead also emphasizes health equity, responsible corporate citizenship, and global health initiatives.
Industries
Nr. of Employees
medium (51-250)
CymaBay Therapeutics
333 Lakeside Drive, Foster City, CA 94404
Patents
Products
HIV and Viral Hepatitis Medications
A portfolio of medicines for HIV, hepatitis B and C, and emerging viruses.
Oncology Therapies
Innovative treatments for cancers, including cell therapy and targeted therapies.
Inflammation Treatments
Therapies aimed at inflammatory diseases with long-acting remissions or cures.
HIV and Viral Hepatitis Medications
A portfolio of medicines for HIV, hepatitis B and C, and emerging viruses.
Oncology Therapies
Innovative treatments for cancers, including cell therapy and targeted therapies.
Inflammation Treatments
Therapies aimed at inflammatory diseases with long-acting remissions or cures.
Services
Providing medical information and reporting adverse events related to Gilead's medicines.
Collaborating with communities worldwide to reduce barriers to care and expand access to medicines.
Supporting patient advocates, healthcare professionals, and nonprofit organizations through the Gilead Foundation and corporate programs.
Investing in scientific research, clinical trials, and innovative therapies across therapeutic areas.
Providing medical information and reporting adverse events related to Gilead's medicines.
Collaborating with communities worldwide to reduce barriers to care and expand access to medicines.
Supporting patient advocates, healthcare professionals, and nonprofit organizations through the Gilead Foundation and corporate programs.
Investing in scientific research, clinical trials, and innovative therapies across therapeutic areas.
News & Updates
Gilead's new medication Yeztugo® (lenacapavir) injection 463.5 mg/1.5 mL has been approved in the U.S. for HIV prevention, offering 6 months of protection.
Gilead emphasizes its mission to build a healthier world through innovative therapies and health equity initiatives.
Gilead invests heavily in research, with a deep pipeline across virology, oncology, and inflammation, including clinical programs and collaborations.
Gilead's efforts extend beyond medicine to include health equity, community partnerships, and global health programs.
Gilead developed the first single-tablet regimen for HIV, transforming care for people living with HIV.
Gilead is the number one funder of HIV programs in the United States, supporting research and community initiatives.
Gilead's new medication Yeztugo® (lenacapavir) injection 463.5 mg/1.5 mL has been approved in the U.S. for HIV prevention, offering 6 months of protection.
Gilead emphasizes its mission to build a healthier world through innovative therapies and health equity initiatives.
Gilead invests heavily in research, with a deep pipeline across virology, oncology, and inflammation, including clinical programs and collaborations.
Gilead's efforts extend beyond medicine to include health equity, community partnerships, and global health programs.
Gilead developed the first single-tablet regimen for HIV, transforming care for people living with HIV.
Gilead is the number one funder of HIV programs in the United States, supporting research and community initiatives.